Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: John R Resseger who wrote (3543)	7/19/2000 12:00:24 PM
From: TA2K	Respond to of 3725

Quarterly Conference Call Announcement JUL 19,2000 5:00 PACIFIC 8:00 EASTERN CA-IMATRON(IMAT) Imatron Inc. Quarterly Conference Call IMATRON INC. QUARTERLY CONFERENCE CALL You are invited to participate in Imatron's conference call to discuss the Company's second quarter financial results. DATE: Tuesday, July 25, 2000 TIME: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) CALL-IN #: 800/816-3054 ACCESS CODE: #99556 For international callers, the dial-in number is 334/323-4100 and the access code is #99556. International conference call help line number is 334/323-8114. If you are unable to participate in the conference call, a replay will be available from Tuesday, July 25, 2000 through Friday, July 28, 2000. The replay number is 888/258-7854. The access code is 00510. International replay number is 703/925-2490. The access code is 00510. If you require additional information, please contact Robin Kelley or Stella Chicilo at 650/583-9964.

To: John R Resseger who wrote (3543)	7/27/2000 9:23:44 AM
From: John T. Hardee	Read Replies (1) \| Respond to of 3725

University of Michigan/Mayo Clinic Research Study Shows Electron Beam Tomography 'EBT' Predicts Coronary Artery Disease in Both Symptomatic and Asymptomatic Patients American Heart Association (AHA) Publishes Paper Supporting Use of EBT Coronary Artery Scan in Determining Need for Additional Cardiac Testing SO. SAN FRANCISCO, Calif.--(BW HealthWire)--July 27, 2000-- Imatron Inc. (Nasdaq:IMAT - news) today announced that the American Heart Association highlighted a publication in its July 25, 2000 issue of Circulation, validating the accuracy of Imatron's EBT scanner in the prediction of heart disease. This important research finding clearly demonstrates significantly better test specificity (the ability to produce a normal result in those persons without cardiac disease) for the EBT coronary artery scan for calcification than had previously been thought. The study, authored by Larry Bielak, MD, and colleagues in the Department of Epidemiology at the University of Michigan in Ann Arbor, Michigan, included 213 patients at high risk, with symptoms of heart disease, who underwent both coronary angiography and the EBT coronary artery scan, together with 765 asymptomatic research subjects who had only the EBT coronary artery scan. All clinical studies were performed at the Mayo Clinic in Rochester, Minnesota and the project was supported by a grant from the National Institutes of Health in Bethesda, Maryland. The paper, entitled, ``Probabilistic Model for Prediction of Angiographically Defined Obstructive Coronary Artery Disease Using Electron Beam Computed Tomography Calcium Score Strata,'' shows that EBT coronary artery calcium scores are predictive of coronary artery disease (CAD) in asymptomatic patients as well as those with symptoms. By eliminating a source of bias commonly present in such research studies, the investigators demonstrated that the specificity of the EBT coronary artery scan for the determination of obstructive CAD was 72.4%, significantly better than the approximately 50% reported previously. EBT coronary artery scan sensitivity, the ability to correctly detect the presence of obstructive disease, was a remarkable 97%. According to senior author Dr. Patricia A. Peyser, there was ``strong evidence'' from calcium scores in patients of either sex as to the presence or absence of obstructive CAD. The authors further stated that results of the EBT coronary artery scan should be combined with everything else that physicians already know about their patients to develop a comprehensive CAD diagnosis and treatment strategy. Moreover, they believe that EBT is ``useful for monitoring the progression of atherosclerosis and for identifying patients who need aggressive treatment to lower risk factors.''